查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1584696

液態切片市場：按生物標記、樣本、類型、技術、適應症、最終用戶、應用分類 - 2025-2030 年全球預測

Liquid Biopsy Market by Biomarkers (Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA), Sample (Blood Based, Urine Based), Type, Technology, Indication, End-User, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年液態切片市場規模預計為60億美元，預計2024年將達到67.2億美元，複合年成長率為12.19%，2030年將達到134.4億美元。

液態切片是一種快速發展的診斷技術，主要分析非固態生物組織（例如血液）以檢測癌症和其他疾病。該技術可識別循環性腫瘤細胞(CTC)、遊離 DNA (cfDNA) 和其他生物標記物，為傳統組織切片檢查提供非侵入性替代方案。液態切片的需求因其在早期癌症檢測、監測腫瘤動態、確定治療策略和克服組織切片檢查的局限性（例如獲取和可行性）方面的潛力而凸顯。應用範圍涵蓋腫瘤學、非侵入性產前檢測 (NIPT) 和移植監測，最終用途為醫院、實驗室和學術機構。

主要市場統計
基準年[2023] 60億美元
預測年份 [2024] 67.2億美元
預測年份 [2030] 134.4億美元
複合年成長率（%） 12.19%

關鍵的市場成長要素包括技術進步、癌症發生率增加以及個人化醫療意識的增強。最新的機會在於擴大即時癌症監測和精準腫瘤學的應用，解決對非侵入性診斷工具的高度未滿足的需求。公司可以透過投資研究來提高檢測靈敏度和特異性並與醫療保健提供者夥伴關係來加速採用來制定策略。液態切片市場的挑戰包括監管障礙、高成本以及有關測試準確性和標準化的技術問題。假陽性/陰性的可能性也是一個主要障礙。

我們需要開拓創新領域，例如增強生物資訊學工具以更好地分析複雜的基因組資料、改進檢測技術以捕獲更廣泛的生物標記物以及開發就地檢驗解決方案。它的特點是市場競爭激烈、科學進步迅速、研發合作傾向強烈。形成策略聯盟並投資穩健的臨床試驗的公司更有可能取得成功。總之，液態切片提供了一個有吸引力的機會，但市場成長需要克服技術和監管挑戰，提高測試的成本效益，並展示明確的臨床效用。

市場動態：揭示快速發展的液態切片市場的關鍵市場洞察

供需的動態交互作用正在改變液態切片市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 癌症發生率和盛行率上升
    • 人們越來越偏好非侵入性診斷方法
  • 市場限制因素
    • 循環性腫瘤細胞(CTC) 的豐度低且脆弱
  • 市場機會
    • 微陣列和次世代定序儀(NGS) 的大量使用
    • 擴大液態切片領域癌症研究的潛在資金
  • 市場挑戰
    • 不確定的監管和報銷情況

波特五力：駕馭液態切片市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解液態切片市場的外部影響

外部宏觀環境因素在塑造液態切片市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解液態切片市場的競爭狀況

對液態切片市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣液態切片市場供應商績效評估

FPNV 定位矩陣是評估液態切片市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了液態切片市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，液態切片市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症發生率和盛行率上升
      • 對非侵入性診斷程序的偏好日益增加
    • 抑制因素
      • 循環性腫瘤細胞(CTC) 的存在率較低且性質脆弱
    • 機會
      • 微陣列與次世代定序(NGS) 的重要用途
      • 資助擴大液態切片領域的癌症研究
    • 任務
      • 監管和報銷方案不明確
  • 市場區隔分析
    • 生物標記：多功能遊離 DNA (cfDNA) 辨識遺傳變化的重要用途
    • 樣本：由於其廣泛的臨床應用和強大的資料支持，基於血液的液態生物檢體的使用正在增加。
    • 類型：早期檢測和篩檢癌症症狀的檢測套組使用的演變
    • 技術：使用次世代定序(NGS) 並行分析多個基因已成為首選，可提供更高的資料吞吐量。
    • 適應症：由於乳癌的高盛行率，乳癌液態切片檢測正在迅速增加。
    • 最終用戶：臨床診斷實驗室液態切片測試的使用量激增
    • 應用：液態切片在早期癌症篩檢的指數應用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化
    • 基於主要軌道的治療：2018-2030 年市場規模與預測

第6章液態切片市場：依生物標記分類

  • 遊離DNA
  • 循環性腫瘤細胞
  • 循環腫瘤DNA
  • 細胞外囊泡

第7章液態切片市場：按樣本

  • 以血液為基礎
  • 基於尿液

第8章液態切片市場：按類型

  • 檢測試劑套件
  • 裝置
  • 服務

第9章液態切片市場：依技術分類

  • 使用NGS進行多基因平行分析
  • 使用 PCR 微陣列進行單基因分析

第10章液態切片市場：依適應症分類

  • 癌症適應症
    • 乳癌
    • 大腸直腸癌
    • 肺癌
    • 惡性黑色素瘤
    • 攝護腺癌
  • 非癌症適應症

第11章液態切片市場：按最終用戶分類

  • 學術研究中心
  • 臨床診斷實驗室
  • 醫院
  • 醫生辦公室檢查室

第12章液態切片市場：依應用分類

  • 早期癌症篩檢
  • 復發監測
  • 治療方法選擇
  • 治療監測

第13章美洲液態切片市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第14章亞太液態切片市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第15章歐洲、中東和非洲液態切片市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • FDA核准FoundationOne Liquid CDx 作為進行性前列腺癌的標靶治療
    • Labcorp 透過新的液態切片服務擴展精準腫瘤學產品組合，以增強癌症診斷和患者照護
    • Personalis Inc. 推出商業癌症 MRD 測試，利用先進的基因組技術徹底改變診斷
    • 皇家馬斯登 NHS 基金會信託與 Guardant Health 合作夥伴透過先進的液態切片測試增強肺癌檢測和治療
    • 佛羅裡達州採用 DiaCarta 的 RadTox 測試進行早期癌症治療，促進全州患者照護
    • GediCube 收購 Cyclomics 增加了液態切片領域的創新和市場覆蓋範圍
    • Myriad Genetics 透過策略收購 Gateway Genomics 拓展液態切片市場
    • Veracyte Inc. 收購 C2i Genomics Ltd.，利用人工智慧增強液態切片技術改進癌症檢測
    • Illumina 推出先進的液態切片檢測，以增強基因組分析和個人化癌症治療
    • 加州大學洛杉磯分校獲得 460 萬美元資金用於創新液態切片技術，以加強癌症檢測和管理
    • 德爾福診斷公司的創新血液檢測旨在加強肺癌篩檢並改善患者治療結果
    • Harbinger Health 籌集 1.4 億美元 B 輪融資，利用液態切片技術推進早期癌症檢測
  • 戰略分析和建議
    • F.霍夫曼羅氏有限公司
    • Illumina公司
    • 凱傑
    • 嘉德健康有限公司

公司名單

  • ANGLE PLC
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocartis NV
  • CellMax Life, Inc.
  • Danaher Corporation
  • DiaCarta, Inc.
  • Dxcover Limited
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Laboratory Dr. med. Pachmann
  • Lucence Health Inc.
  • LungLife AI, Inc.
  • MDxHealth SA
  • Menarini Silicon Biosystems SpA
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Neogenomics, Inc.
  • OncoDNA SA
  • PerkinElmer, Inc.
  • Personalis, Inc.
  • QIAGEN NV
  • SAGA Diagnostics AB
  • Strand Life Sciences Pvt Ltd.
  • Sysmex Corporation
  • Tempus AI, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-43470FC608C8

The Liquid Biopsy Market was valued at USD 6.00 billion in 2023, expected to reach USD 6.72 billion in 2024, and is projected to grow at a CAGR of 12.19%, to USD 13.44 billion by 2030.

Liquid biopsy is a rapidly growing diagnostic technology that involves analyzing non-solid biological tissues, primarily blood, to detect cancer and other conditions. The technique identifies circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other biomarkers, offering a non-invasive alternative to traditional tissue biopsies. The necessity of liquid biopsy is underscored by its potential for early cancer detection, monitoring tumor dynamics, guiding treatment decisions, and overcoming the limitations of tissue biopsy, such as accessibility and feasibility. Its applications extend to oncology, non-invasive prenatal testing (NIPT), and transplant monitoring, while end-use spans hospitals, research laboratories, and academic institutions.

KEY MARKET STATISTICS
Base Year [2023] USD 6.00 billion
Estimated Year [2024] USD 6.72 billion
Forecast Year [2030] USD 13.44 billion
CAGR (%) 12.19%

Key market growth factors include technological advancements, increasing cancer prevalence, and growing awareness of personalized medicine. The latest opportunities lie in expanding applications in real-time cancer monitoring and precision oncology, addressing the high unmet need for non-invasive diagnostic tools. Companies can strategize by investing in research to improve detection sensitivity and specificity, and by forming partnerships with healthcare providers to accelerate adoption. Challenges in the liquid biopsy market include regulatory hurdles, high costs, and technical issues related to the accuracy and standardization of tests. The potential for false positives/negatives also poses a significant barrier.

Innovative areas ripe for exploration include enhancing bioinformatics tools to better analyze complex genomic data, improving assay technologies for broader biomarker capture, and developing point-of-care testing solutions. The liquid biopsy market is characterized by fierce competition, rapid scientific progression, and a strong inclination toward collaborative efforts for research and development. Firms engaging in strategic alliances and investing in robust clinical trials are more likely to succeed. In summary, while liquid biopsy offers compelling opportunities, its market growth is contingent upon overcoming technical and regulatory challenges, improving the cost-effectiveness of tests, and demonstrating clear clinical utility.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Liquid Biopsy Market

The Liquid Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence and prevalence of cancer
    • Increasing preference for noninvasive diagnostic procedures
  • Market Restraints
    • Low abundance and fragile nature of the circulating tumor cells (CTCs)
  • Market Opportunities
    • Significant use of microarrays and next-generation sequencing (NGS)
    • Availability of funding to expand cancer research in the field of liquid biopsy
  • Market Challenges
    • Unclear regulatory and reimbursement scenario

Porter's Five Forces: A Strategic Tool for Navigating the Liquid Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Liquid Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Liquid Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Liquid Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Liquid Biopsy Market

A detailed market share analysis in the Liquid Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Liquid Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Liquid Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Liquid Biopsy Market

A strategic analysis of the Liquid Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include ANGLE PLC, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocartis NV, CellMax Life, Inc., Danaher Corporation, DiaCarta, Inc., Dxcover Limited, Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, Laboratory Dr. med. Pachmann, Lucence Health Inc., LungLife AI, Inc., MDxHealth SA, Menarini Silicon Biosystems SpA, Merck KGaA, Myriad Genetics, Inc., Natera, Inc., Neogenomics, Inc., OncoDNA SA, PerkinElmer, Inc., Personalis, Inc., QIAGEN N.V., SAGA Diagnostics AB, Strand Life Sciences Pvt Ltd., Sysmex Corporation, Tempus AI, Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Biomarkers, market is studied across Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, and Extracellular Vesicles.
  • Based on Sample, market is studied across Blood Based and Urine Based.
  • Based on Type, market is studied across Assay Kits, Instruments, and Services.
  • Based on Technology, market is studied across Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays.
  • Based on Indication, market is studied across Cancer Indication and Non-Cancer Indication. The Cancer Indication is further studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer.
  • Based on End-User, market is studied across Academic & Research Centers, Clinical Diagnostic Laboratories, Hospitals, and Physician's Office Laboratories.
  • Based on Application, market is studied across Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence and prevalence of cancer
      • 5.1.1.2. Increasing preference for noninvasive diagnostic procedures
    • 5.1.2. Restraints
      • 5.1.2.1. Low abundance and fragile nature of the circulating tumor cells (CTCs)
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant use of microarrays and next-generation sequencing (NGS)
      • 5.1.3.2. Availability of funding to expand cancer research in the field of liquid biopsy
    • 5.1.4. Challenges
      • 5.1.4.1. Unclear regulatory and reimbursement scenario
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Biomarkers: Significant utilization of cell-free DNA (cfDNA) versatile in identifying genetic changes
    • 5.2.2. Sample: Rising usage of blood-based liquid biopsies owing to their broad clinical applications and robust data support
    • 5.2.3. Type: Evolving usage of assay kits for early detection and screening of cancer symptoms
    • 5.2.4. Technology: Increasing preference for the multi-gene parallel analysis using next-generation sequencing (NGS), offering higher throughput data
    • 5.2.5. Indication: Burgeoning preference for liquid biopsy tests for breast cancer due to its high prevalence
    • 5.2.6. End-User: Proliferating usage of the liquid biopsy test across the clinical diagnostic laboratories
    • 5.2.7. Application: Exponential utilization of the liquid biopsy for early cancer screening
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization
    • 5.5.1. Maintrac-based Treatment: Mraket size and forecast 2018-2030 (USD Million)

6. Liquid Biopsy Market, by Biomarkers

  • 6.1. Introduction
  • 6.2. Cell-free DNA
  • 6.3. Circulating Tumor Cells
  • 6.4. Circulating Tumor DNA
  • 6.5. Extracellular Vesicles

7. Liquid Biopsy Market, by Sample

  • 7.1. Introduction
  • 7.2. Blood Based
  • 7.3. Urine Based

8. Liquid Biopsy Market, by Type

  • 8.1. Introduction
  • 8.2. Assay Kits
  • 8.3. Instruments
  • 8.4. Services

9. Liquid Biopsy Market, by Technology

  • 9.1. Introduction
  • 9.2. Multi-gene Parallel Analysis using NGS
  • 9.3. Single-gene Analysis using PCR Microarrays

10. Liquid Biopsy Market, by Indication

  • 10.1. Introduction
  • 10.2. Cancer Indication
    • 10.2.1. Breast Cancer
    • 10.2.2. Colorectal Cancer
    • 10.2.3. Lung Cancer
    • 10.2.4. Melanoma
    • 10.2.5. Prostate Cancer
  • 10.3. Non-Cancer Indication

11. Liquid Biopsy Market, by End-User

  • 11.1. Introduction
  • 11.2. Academic & Research Centers
  • 11.3. Clinical Diagnostic Laboratories
  • 11.4. Hospitals
  • 11.5. Physician's Office Laboratories

12. Liquid Biopsy Market, by Application

  • 12.1. Introduction
  • 12.2. Early Cancer Screening
  • 12.3. Recurrence Monitoring
  • 12.4. Therapy Selection
  • 12.5. Treatment Monitoring

13. Americas Liquid Biopsy Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Liquid Biopsy Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Liquid Biopsy Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. FDA Approves FoundationOne Liquid CDx for Targeted Treatment of Advanced Prostate Cancer
    • 16.3.2. Labcorp Expands Precision Oncology Portfolio with New Liquid Biopsy Services, Strengthening Cancer Diagnostics and Patient Care
    • 16.3.3. Personalis Inc. Launches Commercialized Cancer MRD Testing to Revolutionize Diagnostics with Advanced Genomic Technologies
    • 16.3.4. Royal Marsden NHS Foundation Trust and Guardant Health Partner to Enhance Lung Cancer Detection and Treatment with Advanced Liquid Biopsy Tests
    • 16.3.5. Florida Adopts DiaCarta's RadTox Test for Early Cancer Treatment Response, Advancing Statewide Patient Care
    • 16.3.6. GediCube's Acquisition of Cyclomics to Boost Innovation and Market Reach in Liquid Biopsy Sector
    • 16.3.7. Myriad Genetics Expands in Liquid Biopsy Market with Strategic Acquisition of Gateway Genomics
    • 16.3.8. Veracyte Inc. Acquires C2i Genomics Ltd. to Elevate Cancer Detection with AI-Enhanced Liquid Biopsy Technology
    • 16.3.9. Illumina Inc. Unveils Advanced Liquid Biopsy Assay for Enhanced Genomic Profiling and Personalized Cancer Treatment
    • 16.3.10. UCLA Secures USD 4.6 Million to Innovate Liquid Biopsy Technology, Aiming for Enhanced Cancer Detection and Management
    • 16.3.11. Innovative Blood Test by Delfi Diagnostics Aims to Enhance Lung Cancer Screening and Improve Patient Outcomes
    • 16.3.12. Harbinger Health Raises USD 140M in Series B to Advance Early Cancer Detection with Liquid Biopsy Technology
  • 16.4. Strategy Analysis & Recommendation
    • 16.4.1. F. Hoffmann-La Roche Ltd.
    • 16.4.2. Illumina Inc.
    • 16.4.3. QIAGEN N.V.
    • 16.4.4. Guardant Health, Inc.

Companies Mentioned

  • 1. ANGLE PLC
  • 2. Bio-Rad Laboratories, Inc.
  • 3. Bio-Techne Corporation
  • 4. Biocartis NV
  • 5. CellMax Life, Inc.
  • 6. Danaher Corporation
  • 7. DiaCarta, Inc.
  • 8. Dxcover Limited
  • 9. Epic Sciences Inc.
  • 10. Exact Sciences Corporation
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Guardant Health, Inc.
  • 13. Illumina, Inc.
  • 14. Laboratory Corporation of America Holdings
  • 15. Laboratory Dr. med. Pachmann
  • 16. Lucence Health Inc.
  • 17. LungLife AI, Inc.
  • 18. MDxHealth SA
  • 19. Menarini Silicon Biosystems SpA
  • 20. Merck KGaA
  • 21. Myriad Genetics, Inc.
  • 22. Natera, Inc.
  • 23. Neogenomics, Inc.
  • 24. OncoDNA SA
  • 25. PerkinElmer, Inc.
  • 26. Personalis, Inc.
  • 27. QIAGEN N.V.
  • 28. SAGA Diagnostics AB
  • 29. Strand Life Sciences Pvt Ltd.
  • 30. Sysmex Corporation
  • 31. Tempus AI, Inc.
  • 32. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. LIQUID BIOPSY MARKET RESEARCH PROCESS
  • FIGURE 2. LIQUID BIOPSY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LIQUID BIOPSY MARKET DYNAMICS
  • TABLE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BLOOD BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY URINE BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL LIQUID BIOPSY MARKET SIZE, BY NON-CANCER INDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PHYSICIAN'S OFFICE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL LIQUID BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 308. RUSSIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 316. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 324. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 332. SPAIN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 340. SWEDEN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 346. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 348. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 349. TURKEY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 353. TURKEY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 354. TURKEY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 355. TURKEY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 356. TURKEY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 357. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 358. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 365. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 366. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 367. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 368. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 369. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 370. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 371. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 372. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 373. LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 374. LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023